CDX2 and ovarian carcinoma: Stratified by cancer types of the included studies, the CDX2 expression levels in colorectal cancer (OR: 0.80, 95%CI: [0.20,3.25], P = 0.75, I2 = 79%) and ovarian cancer (OR: 1.23, 95%CI: [0.65,2.34], P = 0.52) were irrelevant to disease relapse (Figure 8).